Multi-Kinase Inhibitor with Anti-p38γ Activity in Cutaneous T-Cell Lymphoma

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• Current therapies for cutaneous T-cell lymphoma (CTCL) show limited efficacy and drug resistance, particularly in advanced stages.
• There is a critical need to understand molecular drivers of CTCL for developing targeted treatments.
• p38γ, a mitogen-activated protein kinase, is upregulated in CTCL and essential for malignant T-cell proliferation.

Purpose of the Study:

• To investigate the role of p38γ in CTCL pathogenesis.
• To identify and evaluate potent inhibitors of p38γ for potential therapeutic application in CTCL.
• To assess the efficacy of a specific p38γ inhibitor, PIK75, in preclinical models of CTCL.

Main Methods:

• High-throughput screening to identify p38γ inhibitors.
• In vitro studies using CTCL cell lines and healthy T cells.
• In vivo studies using mouse xenograft models of CTCL.
• Assessment of PIK75's selectivity, cytotoxicity, tumor reduction, and target engagement (p38γ activity and DLGH1 phosphorylation).

Main Results:

• p38γ gene expression is significantly elevated in CTCL samples compared to healthy T cells.
• Gene silencing of p38γ reduces CTCL cell viability.
• The p38γ inhibitor PIK75 selectively kills malignant CD4+ CTCL cells at nanomolar concentrations while sparing healthy CD4+ cells.
• PIK75 treatment significantly reduces tumor size in CTCL mouse xenografts.
• PIK75 effectively inhibits p38γ enzymatic activity and its substrate DLGH1 phosphorylation in CTCL cells and tumors.

Conclusions:

• p38γ plays a crucial role in CTCL pathogenesis.
• PIK75 demonstrates potent and selective anti-CTCL activity in preclinical models.
• PIK75 serves as a promising scaffold for developing novel, more selective p38γ inhibitors for CTCL treatment.